Format

Send to

Choose Destination
J Clin Neurosci. 2019 Sep 3. pii: S0967-5868(19)30090-6. doi: 10.1016/j.jocn.2019.08.082. [Epub ahead of print]

Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients.

Author information

1
Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
2
Center for Medical Genetics, Central South University, Changsha, Hunan, PR China.
3
Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
4
Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China; Center for Medical Genetics, Central South University, Changsha, Hunan, PR China; National Clinical Research Center for Geriatric Diseases, Changsha, Hunan, PR China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, PR China.
5
Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, PR China. Electronic address: 18759036@qq.com.

Abstract

microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, changes in microRNAs are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues in patients of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis and depression. Compared with other bodily fluids, CSF is the most accurate at representing the pathological processes of the brain. To understand whether microRNA expression may be dysregulated in the patients of PD, and to further discover potential diagnostic biomarkers and promising therapeutic targets for PD, we used real-time polymerase chain reaction (RT-PCR) to compare CSF microRNAs from 20 PD patients, 13 AD patients and 27 controls with other neurologic disorders such as encephalitis and Guillain-Barre syndrome. Finally, we found that the mean expression level of hsa-miR-626 was significantly reduced in the CSF of patients with PD compared with AD and controls. Our approach potentially identified a biomarker in CSF that upon further investigation, could be used for the detection, diagnosis, and monitoring of PD in combination with other PD biomarkers.

KEYWORDS:

Biomarker; Cerebrospinal fluid; Parkinson’s disease; hsa-miR-626; microRNAs

PMID:
31492481
DOI:
10.1016/j.jocn.2019.08.082

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center